In this way, other studies have also identified different compounds capable of increasing different AML antigens on leukemic cells and with that, the efficacy of CAR-T cell therapy, as ATRA treatment of AML cell lines and primary samples, which increases CD38 expression on their surface (Yoshida et al., 2016), or the increase of FLT3 in AML cells following treatment with gilteritinib (Li et al., 2022) or crenolanib (Jetani et al., 2018). This evidence concerns the gene CD38 and acute myeloid leukemia.